NYSE: WATWaters Corp Stock
$346.37-2.09 (-0.6%)
Updated May 23, 2025
WAT Price
$346.37
Fair Value Price
N/A
Market Cap
$20.61B
52 Week Low
$279.24
52 Week High
$423.56
P/E
31.32x
P/B
10.5x
P/S
7.22x
PEG
2.53x
Dividend Yield
N/A
Revenue
$2.98B
Earnings
$657.02M
Gross Margin
59.3%
Operating Margin
28.87%
Profit Margin
22%
Debt to Equity
1.34
Operating Cash Flow
$759M
Beta
0.94
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
WAT Overview
Waters Corporation manufactures, sells, and services ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, and other consumable products. Its MS technology instruments are used in clinical trial drug testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Waters was founded in 1958 and is headquartered in Milford, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine WAT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
C
WAT
Ranked#10 of 43
Ranked#10 of 43
Be the first to know about important WAT news, forecast changes, insider trades & much more!
WAT News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how WAT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
WAT ($346.37) is trading above its intrinsic value of $105.58, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
WAT is poor value based on its earnings relative to its share price (31.32x), compared to the US market average (21.18x)
P/E vs Market Valuation
WAT is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more WAT due diligence checks available for Premium users.
Valuation
WAT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
31.32x
Industry
18.92x
Market
21.18x
WAT is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
WAT is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
WAT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.5x
Industry
3.28x
WAT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
WAT price to earnings growth (PEG)
For valuing profitable companies with growth potential
WAT is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
WAT's financial health
Profit margin
Revenue
$661.7M
Net Income
$121.4M
Profit Margin
18.3%
WAT's Earnings (EBIT) of $861.33M... subscribe to Premium to read more.
Interest Coverage Financials
WAT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$4.6B
Liabilities
$2.6B
Debt to equity
1.34
WAT's short-term assets ($1.74B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
WAT's short-term assets ($1.74B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
WAT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
WAT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$259.6M
Investing
-$26.2M
Financing
-$173.2M
WAT's operating cash flow ($758.81M)... subscribe to Premium to read more.
Debt Coverage Financials
WAT vs Diagnostic & Research Stocks
Waters Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.